吸入糖皮质激素与COPD患者全因死亡风险的关联:60项随机对照试验的Meta分析
该Meta分析纳入60项RCT共103,034例COPD患者,比较含ICS吸入治疗与不含ICS吸入治疗。含ICS吸入治疗尤其三联疗法与全因死亡风险降低相关,血嗜酸性粒细胞≥200/μL是最强预测因素。
要点
- 含ICS吸入治疗与COPD患者全因死亡风险降低相关,三联疗法关联更强。
- 血嗜酸性粒细胞≥200/μL或≥2%是死亡风险降低的最强预测因素。
- 既往频繁中重度急性加重、GOLD III-IV期、年龄<65岁、BMI≥25 kg/m2亦为预测因素。
核心结论
- 含ICS吸入治疗尤其三联疗法超过6个月与COPD患者全因死亡风险降低相关。
- 该关联的预测因素包括药物因素和患者特征,其中血嗜酸性粒细胞≥200/μL为最强预测因素。
研究设计与样本
- 检索PubMed、Cochrane Library、Embase和ClinicalTrials.gov的随机对照试验。
- 共纳入60项RCT,103,034例COPD患者。
- 合并结果采用Peto OR及相应95%CI计算。
主要发现
- 含ICS吸入治疗对比不含ICS吸入治疗的全因死亡Peto OR为0.90(95%CI 0.84-0.97)。
- 三联疗法的全因死亡Peto OR为0.73(95%CI 0.59-0.91)。
- 治疗时长>6个月的Peto OR为0.90(95%CI 0.83-0.97)。
- 中等剂量ICS的Peto OR为0.71(95%CI 0.56-0.91),低剂量ICS的Peto OR为0.88(95%CI 0.79-0.97)。
- 布地奈德的Peto OR为0.75(95%CI 0.59-0.94)。
关键数值与推荐
- 血嗜酸性粒细胞≥200/μL或百分比≥2%为预测因素,其中≥200/μL的Peto OR为0.58(95%CI 0.36-0.95)。
- 预测因素包括既往一年≥2次中重度急性加重、GOLD III或IV期、年龄<65岁、BMI≥25 kg/m2。
临床怎么用
- 对COPD患者考虑含ICS吸入治疗尤其三联疗法超过6个月以降低全因死亡风险。
- 优先在血嗜酸性粒细胞≥200/μL或≥2%、既往频繁急性加重、GOLD III-IV期、年龄<65岁、BMI≥25 kg/m2的患者中评估ICS获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inhaled corticosteroids (ICSs) have been used widely in the maintenance therapy of COPD. However, whether inhaled therapy containing ICSs can reduce the all-cause mortality risk and the possible benefited patient subgroups is unclear. RESEARCH QUESTION: Does inhaled therapy containing ICSs reduce the all-cause mortality risk in patients with COPD compared with other inhaled therapies not containing ICSs? STUDY DESIGN AND METHODS: We searched PubMed, Cochrane Library, Embase, and ClinicalTrials.gov for relevant randomized clinical trials (RCTs). Pooled results were calculated using Peto ORs with corresponding 95% CIs. RESULTS: Sixty RCTs enrolling 103,034 patients were analyzed. Inhaled therapy containing ICSs (Peto OR, 0.90; 95% CI, 0.84-0.97), especially triple therapy (Peto OR, 0.73; 95% CI, 0.59-0.91), was associated with a reduction in the all-cause mortality risk among patients with COPD when compared with inhaled therapy without ICSs. Subgroup analyses revealed that treatment duration of > 6 months (Peto OR, 0.90; 95% CI, 0.83-0.97), medium-dose ICSs (Peto OR, 0.71; 95% CI, 0.56-0.91), low-dose ICSs (Peto OR, 0.88; 95% CI, 0.79-0.97), and budesonide (Peto OR, 0.75; 95% CI, 0.59-0.94) were involved in this association. The predictors of this association included eosinophil counts of ≥ 200/μL or percentage of ≥ 2%, documented history of ≥ 2 moderate and severe exacerbations in the previous year, Global Initiative for Chronic Obstructive Lung Disease stages III or IV, age younger than 65 years, and BMI of ≥ 25 kg/m2, among which eosinophil counts of ≥ 200/μL (Peto OR, 0.58; 95% CI, 0.36-0.95) were the strongest predictor. INTERPRETATION: Inhaled therapy containing ICSs, especially triple therapy, of longer than 6 months was associated with a reduction in the all-cause mortality risk in patients with COPD. The predictors of this association included medication factors and patient characteristics, among which eosinophil counts of ≥ 200/μL were the strongest predictor. TRIAL REGISTRY: PROSPERO; No.: CRD42022304725; URL: https://www.crd.york.ac.uk/prospero/.
引用
- Chen H, Deng ZX, Sun J, et al. Association of Inhaled Corticosteroids With All-Cause Mortality Risk in Patients With COPD: A Meta-analysis of 60 Randomized Controlled Trials. Chest. 2022. PMID: 35921883. doi:10.1016/j.chest.2022.07.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。